Crossmark

Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials

Published Online: 2025-04-11

Published Print: 2025-06

Authors

Shiga, Kaname https://orcid.org/0009-0002-3390-464X
Shibata, Taro

Miyata, Toshio
License Information

Text and Data Mining valid from 2025-04-11

Version of Record valid from 2025-04-11
More Information

Article History

Received: 14 November 2024

Accepted: 23 March 2025

First Online: 11 April 2025

Declarations

:

: Kaname Shiga is an employee of Janssen Pharmaceutical K.K., a subsidiary of Johnson & Johnson Innovative Medicine, Raritan, NJ, USA. Taro Shibata and Toshio Miyata have no conflict of interest.

Document is current